Circulating insulin-like growth factor-I (IGF-I) levels have been shown to be related to risk of prostate cancer in epidemiologic studies. While specific genetic loci responsible for interindividual variation in circulating IGF-I levels in normal men have not been identified, candidate genes include those involved in the growth hormone (GH)-IGF-I axis such as the hypothalamic factors GH releasing hormone (GHRH) and somatostatin and their receptors. To investigate the role of the GH-IGF-I axis on in vivo prostate carcinogenesis and neoplastic progression, we generated mice genetically predisposed to prostate cancer (the TRAMP model) to be homozygous for lit, a mutation that inactivates the GHRH receptor (GHRH-R) and reduces circulating levels of GH and IGF-I. The lit mutation significantly reduced the percentage of the prostate gland showing neoplastic changes at 35 weeks of age (P ¼ 0.0005) and was also associated with improved survival (Po0.01). These data provide an example of a germ line mutation that reduces risk in an experimental prostate carcinogenesis model. The results suggest that prostate carcinogenesis and progression may be influenced by germ line variation of genes encoding signalling molecules in the GH-IGF-I axis.
Recent prospective studies have revealed a positive association between serum insulin-like growth factor-I (IGF-I) and prostate cancer risk (Chan et al., 1998; Wolk et al., 1998; Shaneyfelt et al., 2000; Pollak, 2001; Pollak et al., 2004; Renehan et al., 2004; Stattin et al., 2004) . Both genetic and lifestyle factors influence IGF-I levels (Harrela et al., 1996) . Epidemiologic data showing variation of prostate cancer risk according to IGF-I levels are biologically plausible given that normal prostate epithelial cells (Cohen et al., 1991) as well as prostate cancer cells (Culig et al., 1994; Pollak et al., 1999; Hellawell et al., 2002) are IGF-I responsive. While specific genetic loci responsible for interindividual variation in circulating IGF-I levels in normal men have not been identified, candidate genes include those involved in the growth hormone (GH)-IGF-I axis such as the hypothalamic factors GH releasing hormone (GHRH) and somatostatin and their receptors. A mutation (lit) in the murine GHRH-R gene is associated with a loss of receptor function that leads to low systemic GH and IGF-I levels and to small body size (Jansson et al., 1986; Godfrey et al., 1993; Lin et al., 1993) but does not affect androgen levels (reviewed in Chandrashekar et al., 2004) .
In this study, we used the transgenic adenocarcinoma of the mouse prostate model (TRAMP) that was developed using a -426/ þ 28 bp fragment of the rat probasin regulatory sequence to specifically target expression of SV40 early genes to the prostatic epithelium (Greenberg et al., 1995; Gingrich et al., 1999; Kaplan-Lefko et al., 2003) . The changes that occur during prostate carcinogenesis in these mice highly resemble human prostate transformation (Greenberg et al., 1995; Gingrich et al., 1999; Kaplan-Lefko et al., 2003) and take place in the setting of normal serum androgen levels (Wang et al., 2004) . We generated TRAMP mice (C57BL/6 background) to be homozygous for the lit mutation and compared prostate incidence and progression in TRAMP and TRAMP/lit/lit animals, over a 35-week period.
All TRAMP control mice (n ¼ 19) developed prostate cancer and 74% either died prior to the 35-week time point, or had to be killed due to advanced disease, in contrast to only 18% of TRAMP/lit/lit mice (n ¼ 17) (Figure 1a) . The difference in survival is significant (Po0.01). All animals surviving to the 35-week time point were weighed and examined for gross organ abnormalities at necropsy. The gross pathology showed that the TRAMP mice displayed gross abnormality of the seminal vesicles and tissue invasion while the TRAMP/lit/lit mice appeared normal without any gross abnormality or tissue invasion of the seminal vesicles. We observed that of the five TRAMP mice that survived to that time-point, 100% showed gross evidence of prostate and seminal vesicle neoplasia, in contrast to only 14% of the surviving 14 TRAMP/lit/lit mice.
As expected, TRAMP/lit/lit mice were smaller in size than TRAMP mice. The mean body weight for TRAMP/lit/lit group was found to be 14.2670.28 versus 30.7771.24 g of the control group (P ¼ 0.001). The weight of the genito-urinary organs relative to body weight was reduced in TRAMP/lit/lit animals as compared to controls (mean ratio 0.0470.01 versus 0.1070.01 respectively, P ¼ 0.0019).
Microscopic examination of the prostate glands revealed a significant impact of the lit mutation on prostate neoplasia (Figure 1b and c). Among TRAMP controls, 22.972.2% of the prostate gland at 35 weeks of age was found to be histologically normal, 19.974.5% exhibited prostatic intraepithelial neoplasia (PIN), and 57.375.8% showed invasive cancer, as compared to 41.675.5, 31.073.4 and 27.474 .8% respectively in the homozygous lit mice (Figure 2a) . The difference between the percentage of the prostate gland with invasive cancer between the TRAMP control and the TRAMP/lit/lit groups is significant (P ¼ 0.0005). While the TRAMP mice homozygous for the lit mutation had far less invasive cancer at the 35-week time point than the TRAMP controls, we noted a slight increase in PIN in the former as compared to the latter group. This may suggest that the IGF-I deficiency reduced the rate of neoplastic progression from PIN to frank neoplasia.
The histopathology of the seminal vesicles also varied significantly as a function of genotype (Figures 1d, e and  2b ). In the TRAMP mice, the seminal vesicles were significantly enlarged while TRAMP/lit/lit seminal vesicles were normal in size. Among TRAMP control mice, 64.678.8% of the seminal vesicles were scored as normal, as compared to 93.671.9% in the TRAMP/lit/ lit group (P ¼ 0.001). The presence of invasive adenocarcinoma was rare in the seminal vesicles, and was The lit mutation delays prostate cancer progression N Majeed et al confined to the TRAMP controls, where it involved on average 2.572.1% of the tissue. Phylloides-like histopathology, indicative of obstruction, was found to be 32.978.8% in TRAMP controls, but only 6.471.9% in TRAMP/lit/lit animals (P ¼ 0.0024). As anticipated, TRAMP/lit/lit mice had lower serum IGF-I and insulin-like growth factor binding protein-3 (IGFBP-3) levels than TRAMP control mice. The mean serum IGF-I levels of TRAMP/lit/lit measured 19.4178.64 versus 305.83781.40 ng/ml in controls (P ¼ 0.025). Western ligand blot analysis of serum IGFBP-3 showed a very weak doublet band representing the anticipated low serum levels of IGFBP-3 in the IGF-I-deficient TRAMP mice (data not shown).
As a secondary end point, we used Ki-67 labeling to compare proliferative rate between TRAMP controls and TRAMP/lit/lit mice in both normal and neoplastic tissue at the 35-week time point. Although we had insufficient tissue for formal quantitative analysis of this end point, Ki-67 staining showed reduced tumor cell proliferation in the TRAMP/lit/lit animals compared to the TRAMP controls (Figure 3c and d) . The difference in proliferation in the untransformed (at-risk) tissue between controls and TRAMP/lit/lit animals was in the same direction, but less marked (Figure 3a and b) .
Our data identify lit as a germ-line mutation that confers protection against prostate carcinogenesis. Although it has been suggested that GHRH-R is present and functional in prostate cells (Chopin and Herington, 2001; Letsch et al., 2003) , we were unable to detect GHRH-R transcripts in either the normal or the neoplastic prostate tissue of TRAMP or TRAMP/lit/ lit mice (Figure 4) . We therefore speculate that in contrast to classic oncogenes and tumor suppressor genes, which act at the cellular level, GHRH-R influences carcinogenesis indirectly, acting at the level Total cellular RNA was isolated using the Qiagen Rneasy mini-kit (prostate tissue) (Mississauga, ONT, Canada) and with Trizol (pituitary gland) (Invitrogen/Canada life Technologies, Burlington, ONT, Canada), according to the manufacturer's protocols. Total RNA from mouse prostates (20-320 ng) and anterior pituitaries (2.5 ng) was subjected to one-step RT-PCR using reagents and protocol of the Titan One Tube RT-PCR System kit (Roche Diagnostics, Laval, QC, Canada) using primers for mouse GHRH-R (20 pmol) (Peng et al., 2001) and mouse GAPDH (300 pmol) (Aleppo et al., 1997) . RT-PCR reaction was performed using a Biometra T Gradient PCR (Montreal Biotech Inc., Kirkland, QC, Canada), with the following cycle profile: 30 min at 50.01C; denaturation at 95.01C for 3 min, annealing at 66.01C for 70 s, elongation at 72.01C for 60 s followed by 39 cycles at 95.01C for 60 s, at 66.01C for 70 s, at 72.01C for 60 s, and a final cycle at 95.01C for 70 s, 66.01C for 60 s, and a 5-min elongation step at 72.01C. GHRH-R and GAPDH PCR products were analysed by gel electrophoresis on 4.5% nondenaturating polyacrylamide gel (for more details see Supplementary methods). In contrast to the anterior pituitary, very low to background levels were observed in prostate samples, even using 320 ng of prostate total RNA for the RT-PCR reaction in TRAMP prostate samples. Pit: anterior pituitary; Pro: prostate
The lit mutation delays prostate cancer progression N Majeed et al of whole organism by influencing the levels of GH and IGF-I. While IGF-I signalling has been found to favor survival at the cellular level (O'Connor et al., 2000; Pollak et al., 2004) , activation of the insulin/IGF-I signalling pathway leads to accelerated aging in a variety of model organisms (Guarente and Kenyon, 2000; Kenyon 2001; Dillin et al., 2002; Holzenberger et al., 2002; Tissenbaum and Guarente, 2002; Arantes-Oliveira et al., 2003; Longo and Finch, 2003; Tatar et al., 2003; Pollak et al., 2004) . The lit mutation provides an interesting contrast to the recently described p53 þ /m mutation (Tyner et al., 2002) . Both are associated with substantial reduction in tumor incidence, but the former leads to enhanced longevity (Flurkey et al., 2001) while animals with the latter mutation display an accelerated aging phenotype (Tyner et al., 2002) .
Higher IGF-I levels may facilitate carcinogenesis and/ or early neoplastic progression by increasing the turnover rate of at-risk epithelial cells of the prostate, and/or by decreasing the probability of apoptosis of partially transformed cells. It is of interest that a rare human mutation analogous to the murine lit mutation has been described and also causes growth failure (Wajnrajch et al., 1996; Maheshwari et al., 1998) . It is likely, however, that polymorphic variation of genes related to the GH-IGF-I axis has a greater impact on cancer risk and cancer aggressivity in human populations than inactivating mutations. The GH-IGF-I axis may offer novel molecular targets for prevention and treatment of prostate cancer.
Note added in Proof
Drs L Murphy and J Dodd (University of Manitoba) have recently observed that prostate cancer growth in a similar model is reduced when prostate cancer-prone mice are crossed with IGFBP-3 transgenic mice (personal communication).
Abbreviations IGF-I, insulin-like growth factor I; GH, growth hormone; GHRH-R, growth hormone releasing hormone receptor; IGFBP-3, insulin-like growth factor binding protein-3; TRAMP, transgenic adenocarcinoma of the mouse prostate; PIN, prostatic intraepithelial neoplasia; nt, nucleotide.
